227 related articles for article (PubMed ID: 28823947)
1. Safety, pharmacokinetics and dose-response characteristics of GSK2269557, an inhaled PI3Kδ inhibitor under development for the treatment of COPD.
Cahn A; Hamblin JN; Begg M; Wilson R; Dunsire L; Sriskantharajah S; Montembault M; Leemereise CN; Galinanes-Garcia L; Watz H; Kirsten AM; Fuhr R; Hessel EM
Pulm Pharmacol Ther; 2017 Oct; 46():69-77. PubMed ID: 28823947
[TBL] [Abstract][Full Text] [Related]
2. A Multicentre, Randomized, Double-Blind, Placebo-Controlled, Crossover Study To Investigate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Repeat Doses of Inhaled Nemiralisib in Adults with Persistent, Uncontrolled Asthma.
Khindri S; Cahn A; Begg M; Montembault M; Leemereise C; Cui Y; Hogg A; Wajdner H; Yang S; Robertson J; Hamblin JN; Ludwig-Sengpiel A; Kornmann O; Hessel EM
J Pharmacol Exp Ther; 2018 Dec; 367(3):405-413. PubMed ID: 30217958
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the Safety, Tolerability, and Pharmacokinetics of GSK2269557 (Nemiralisib) Administered Via Dry Powder Inhaler to Healthy Japanese Subjects.
Ino H; Wilson R; Terao T; Ogura H; Igarashi H; Cahn A; Numachi Y
Clin Pharmacol Drug Dev; 2019 Jan; 8(1):78-86. PubMed ID: 30303626
[TBL] [Abstract][Full Text] [Related]
4. Relationship between Pharmacokinetics and Pharmacodynamic Responses in Healthy Smokers Informs a Once-Daily Dosing Regimen for Nemiralisib.
Begg M; Wilson R; Hamblin JN; Montembault M; Green J; Deans A; Amour A; Worsley S; Fantom K; Cui Y; Dear G; Ahmad S; Kielkowska A; Clark J; Boyce M; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):337-344. PubMed ID: 30886125
[TBL] [Abstract][Full Text] [Related]
5. Tiotropium bromide. A review of its use as maintenance therapy in patients with COPD.
Keam SJ; Keating GM
Treat Respir Med; 2004; 3(4):247-68. PubMed ID: 15350163
[TBL] [Abstract][Full Text] [Related]
6. Safety and tolerability of the inhaled phosphodiesterase 4 inhibitor GSK256066 in moderate COPD.
Watz H; Mistry SJ; Lazaar AL;
Pulm Pharmacol Ther; 2013 Oct; 26(5):588-95. PubMed ID: 23701917
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of RPL554, a dual PDE3 and PDE4 inhibitor, in healthy volunteers and in patients with asthma or chronic obstructive pulmonary disease: findings from four clinical trials.
Franciosi LG; Diamant Z; Banner KH; Zuiker R; Morelli N; Kamerling IM; de Kam ML; Burggraaf J; Cohen AF; Cazzola M; Calzetta L; Singh D; Spina D; Walker MJ; Page CP
Lancet Respir Med; 2013 Nov; 1(9):714-27. PubMed ID: 24429275
[TBL] [Abstract][Full Text] [Related]
8. Dose-response to inhaled glycopyrrolate delivered with a novel Co-Suspension™ Delivery Technology metered dose inhaler (MDI) in patients with moderate-to-severe COPD.
Fabbri LM; Kerwin EM; Spangenthal S; Ferguson GT; Rodriguez-Roisin R; Pearle J; Sethi S; Orevillo C; Darken P; St Rose E; Fischer T; Golden M; Dwivedi S; Reisner C
Respir Res; 2016 Sep; 17(1):109. PubMed ID: 27586537
[TBL] [Abstract][Full Text] [Related]
9. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
10. Pharmacodynamics, pharmacokinetics and safety of revefenacin (TD-4208), a long-acting muscarinic antagonist, in patients with chronic obstructive pulmonary disease (COPD): Results of two randomized, double-blind, phase 2 studies.
Quinn D; Barnes CN; Yates W; Bourdet DL; Moran EJ; Potgieter P; Nicholls A; Haumann B; Singh D
Pulm Pharmacol Ther; 2018 Feb; 48():71-79. PubMed ID: 28987804
[TBL] [Abstract][Full Text] [Related]
11. A 28-day, randomized, double-blind, placebo-controlled, parallel group study of nebulized revefenacin in patients with chronic obstructive pulmonary disease.
Pudi KK; Barnes CN; Moran EJ; Haumann B; Kerwin E
Respir Res; 2017 Nov; 18(1):182. PubMed ID: 29096627
[TBL] [Abstract][Full Text] [Related]
12. Translation of Inhaled Drug Optimization Strategies into Clinical Pharmacokinetics and Pharmacodynamics Using GSK2292767A, a Novel Inhaled Phosphoinositide 3-Kinase
Begg M; Edwards CD; Hamblin JN; Pefani E; Wilson R; Gilbert J; Vitulli G; Mallett D; Morrell J; Hingle MI; Uddin S; Ehtesham F; Marotti M; Harrell A; Newman CF; Fernando D; Clark J; Cahn A; Hessel EM
J Pharmacol Exp Ther; 2019 Jun; 369(3):443-453. PubMed ID: 30940692
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of glycopyrrolate/eFlow
Kerwin E; Donohue JF; Goodin T; Tosiello R; Wheeler A; Ferguson GT
Respir Med; 2017 Nov; 132():238-250. PubMed ID: 28838685
[TBL] [Abstract][Full Text] [Related]
14. Safety, tolerability and efficacy of indacaterol, a novel once-daily beta(2)-agonist, in patients with COPD: a 28-day randomised, placebo controlled clinical trial.
Beier J; Chanez P; Martinot JB; Schreurs AJ; Tkácová R; Bao W; Jack D; Higgins M
Pulm Pharmacol Ther; 2007; 20(6):740-9. PubMed ID: 17088091
[TBL] [Abstract][Full Text] [Related]
15. Bronchodilator efficacy of extrafine glycopyrronium bromide: the Glyco 2 study.
Singh D; Scuri M; Collarini S; Vezzoli S; Mariotti F; Muraro A; Acerbi D
Int J Chron Obstruct Pulmon Dis; 2017; 12():2001-2014. PubMed ID: 28744115
[TBL] [Abstract][Full Text] [Related]
16. An Inhaled PI3Kδ Inhibitor Improves Recovery in Acutely Exacerbating COPD Patients: A Randomized Trial.
Cahn A; Hamblin JN; Robertson J; Begg M; Jarvis E; Wilson R; Dear G; Leemereise C; Cui Y; Mizuma M; Montembault M; Van Holsbeke C; Vos W; De Backer W; De Backer J; Hessel EM
Int J Chron Obstruct Pulmon Dis; 2021; 16():1607-1619. PubMed ID: 34113093
[TBL] [Abstract][Full Text] [Related]
17. The efficacy and safety of the novel long-acting β2 agonist vilanterol in patients with COPD: a randomized placebo-controlled trial.
Hanania NA; Feldman G; Zachgo W; Shim JJ; Crim C; Sanford L; Lettis S; Barnhart F; Haumann B
Chest; 2012 Jul; 142(1):119-127. PubMed ID: 22241764
[TBL] [Abstract][Full Text] [Related]
18. Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: A pilot study.
Shute JK; Calzetta L; Cardaci V; di Toro S; Page CP; Cazzola M
Pulm Pharmacol Ther; 2018 Feb; 48():88-96. PubMed ID: 28986203
[TBL] [Abstract][Full Text] [Related]
19. A comparison between inhaled salmeterol and theophylline in the short-term treatment of stable chronic obstructive pulmonary disease.
Broseghini C; Testi R; Polese G; Tosatto R; Rossi A
Pulm Pharmacol Ther; 2005; 18(2):103-8. PubMed ID: 15649852
[TBL] [Abstract][Full Text] [Related]
20. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD.
Kempsford R; Norris V; Siederer S
Pulm Pharmacol Ther; 2013 Apr; 26(2):256-64. PubMed ID: 23232038
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]